Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Sleep medicine · Sleep · 2026-10-13
Secondary analysis
Kanu et al. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analysesDiabetes and endocrinology · Diabetes Care · 2026-10-01
RCTn = 15,220
Sattar et al. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDCardiology · J Am Heart Assoc · 2026-09-09
Meta-analysisn = 6,515
Mansouri et al. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled TrialsSleep medicine · J Clin Sleep Med · 2026-08-31
Secondary analysis
Falcon et al. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSADiabetes and endocrinology · BMJ · 2026-07-08
Meta-analysisn = 99,791
Nong et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysisDermatology · JAMA Dermatol · 2026-07-01
RCTn = 274
Lebwohl et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialCardiology · J Am Coll Cardiol · 2026-06-03
Secondary analysisn = 392
Sattar et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc AnalysisCardiology · JAMA Cardiol · 2026-06-01
Secondary analysisn = 13,165
Nissen et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical TrialDiabetes and endocrinology · Lancet · 2026-05-12
RCTn = 378
Horn et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trialDiabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-05-11
Secondary analysisn = 13,165
Zoungas et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialRheumatology · Arthritis Rheumatol · 2026-03-28
RCTn = 271
Merola et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialRespiratory · Respir Med · 2026-01-29
Meta-analysisn = 1,280
Yang et al. Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysisDiabetes and endocrinology · Diabetes Care · 2026-01-01
RCTn = 24
Snaith et al. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical TrialDiabetes and endocrinology · Diabetologia · 2025-12-19
Secondary analysisn = 1,879
Neves et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 TrialCardiology · N Engl J Med · 2025-12-18
Clinical trialn = 13,299
Nicholls et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes